Ongoing challenges and future directions of human papillomavirus vaccination
https://doi.org/10.30895/2312-7821-2020-8-3-141-150
Abstract
Cervical cancer caused by human papillomavirus (HPV) types 16 and 18 is one of the most common cancer types in women. Other high-risk HPV types may cause vaginal cancer, vulval cancer, penile cancer, anal cancer, head and neck cancer. Low-risk HPV types, such as 6 and 11, can cause anogenital warts and recurrent respiratory papillomatosis. These diseases may be prevented by vaccinating women and men before contracting the virus. The aim of the study was to summarise current data on using vaccines for the prevention of HPV-associated diseases. Currently, there are three HPV vaccines available on the market: Cervarix®, Gardasil®, and Gardasil®9. Extensive clinical and post-licensing studies show that these vaccines are safe and highly effective (up to 100 %) in preventing vaginal, vulval, and cervical intraepithelial neoplasias when administered to patients who were not previously infected with these HPV types. However, there are a number of unresolved issues that encourage further clinical research to find a universal vaccine. First of all, the effectiveness of these vaccines is limited to the HPV types covered by a particular vaccine. It was only in 2011 that the question was raised about the need to vaccinate males. Also, the recommendations on the frequency of vaccination are periodically revised in line with new immunogenicity study results. Reducing the frequency of immunisation is particularly relevant for developing countries with limited financial resources and a high incidence of cervical cancer. Thus, global vaccination programmes, including those with optimal availability and immunisation frequency for developing countries, higher vaccination coverage in terms of age and sex, and expansion of cancer screening programmes are necessary to eliminate HPV worldwide.
Funding: The study was performed without external funding.
About the Authors
O. S. Alyautdina
I. M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Dr. Sci. (Med.), Professor
8/2 Trubetskaya St., Moscow 119991
V. Yu. Prilutskaya
I. M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Scopus Author ID: 57203243192
8/2 Trubetskaya St., Moscow 119991
References
1. Castle PE, Fetterman B, Poitras N, Lorey T, Shaber R, Kinney W. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol. 2009;113(3):595–600. https://doi.org/10.1097/AOG.0b013e3181996ffa
2. Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4(7):e453-63. https://doi.org/10.1016/S2214-109X(16)30099-7
3. Pinidis P, Tsikouras P, Iatrakis G, Zervoudis S, Koukouli Z, Bothou A, et al. Human papilloma virus' life cycle and carcinogenesis. Maedica (Buchar). 2016;11(1):48–54.
4. Tomar A, Kushwah A. Advances in human papilloma virus vaccines: a review. Int J Basic Clin Pharmacol. 2014;3(1):37–43. https://doi.org/10.5455/2319-2003.ijbcp20140237
5. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–27. https://doi.org/10.1056/nejmoa021641
6. Burley M, Roberts S, Parish JL. Epigenetic regulation of human papillomavirus transcription in the productive virus life cycle. Semin Immunopathol. 2020;42(2):159–171. https://doi.org/10.1007/s00281-019-00773-0
7. Pappa KI, Kontostathi G, Lygirou V, Zoidakis J, Anagnou NP. Novel structural approaches concerning HPV proteins: Insight into targeted therapies for cervical cancer (Review). Oncol Rep. 2018;39(4):1547–54. https://doi.org/10.3892/or.2018.6257
8. Harden ME, Munger K. Human papillomavirus molecular biology. Mutat Res Rev Mutat Res. 2017;772:3–12. https://doi.org/10.1016/j.mrrev.2016.07.002
9. Bristol ML, Das D, Morgan IM. Why human papillomaviruses activate the DNA damage response (DDR) and how cellular and viral replication persists in the presence of DDR signaling. Viruses. 2017;9(10):268. https://doi.org/10.3390/v9100268
10. Moody C. Mechanisms by which HPV induces a replication competent environment in differentiating keratinocytes. Viruses. 2017;9(9):261. https://doi.org/10.3390/v9090261
11. Giroglou T, Florin L, Schäfer F, Streeck RE, Sapp M. Human papillomavirus infection requires cell surface heparan sulfate. J Virol. 2001;75(3):1565–70. https://doi.org/10.1128/jvi.75.3.1565-1570.2001
12. Culp TD, Budgeon LR, Marinkovich MP, Meneguzzi G, Christensen ND. Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells. J Virol. 2006;80(18):8940–50. https://doi.org/10.1128/jvi.00724-06
13. Smith JL, Campos SK, Ozbun MA. Human papillomavirus type 31 uses a caveolin 1- and dynamin 2-mediated entry pathway for infection of human keratinocytes. J Virol. 2007;81(18):9922–31. https://doi.org/10.1128/jvi.00988-07
14. Doorbar J, Griffin H. Intrabody strategies for the treatment of human papillomavirus-associated disease. Expert Opin Biol Ther. 2007;7(5):677–89. https://doi.org/10.1517/14712598.7.5.677
15. McKinney CC, Hussmann KL, McBride A. The role of the DNA damage response throughout the papillomavirus life cycle. Viruses. 2015;7(5):2450–69. https://doi.org/10.3390/v7052450
16. Stanley M. Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer. Br J Cancer. 2007;96(9):1320–3. https://doi.org/10.1038/sj.bjc.6603695
17. Henley SA, Dick FA. The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle. Cell Div. 2012;7(1):10. https://doi.org/10.1186/1747-1028-7-10
18. Inoue K, Fry EA. Aberrant expression of p16INK4a in human cancers – a new biomarker? Cancer Rep Rev. 2018;2(2). https://doi.org/10.15761/CRR.1000145
19. Garima, Pandey S, Pandey LK, Saxena AK, Patel N. The role of p53 gene in cervical carcinogenesis. J Obstet Gynaecol India. 2016;66(Suppl 1):383–8. https://doi.org/10.1007/s13224-015-0754-1
20. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst. 1994;86(7):494–9. https://doi.org/10.1093/jnci/86.7.494
21. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer. 2008;113(10 Suppl):3036–46. https://doi.org/10.1002/cncr.23764
22. Cimica V, Galarza JM. Adjuvant formulations for virus-like particle (VLP) based vaccines. Clin Immunol. 2017;183:99–108. https://doi.org/10.1016/j.clim.2017.08.004
23. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al. Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum Vaccin. 2009;5(10):705–19. https://doi.org/10.4161/hv.5.10.9518
24. Ogawa Y, Takei H, Ogawa R, Mihara K. Safety of human papillomavirus vaccines in healthy young women: a meta-analysis of 24 controlled studies. J Pharm Health Care Sci. 2017;3:18. https://doi.org/10.1186/s40780-017-0087-6
25. Phillips A, Patel C, Pillsbury A, Brotherton J, Macartney K. Safety of human papillomavirus vaccines: an updated review. Drug Saf. 2018;41(4):329–46. https://doi.org/10.1007/s40264-017-0625-z
26. Centers for Disease Control and Prevention (CDC). FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59(20):630–2.
27. Kardas-Nelson M. Vaccine uptake and prevalence of HPV related cancers in US men. BMJ. 2019;364:l1210. https://doi.org/10.1136/bmj.l1210
28. Sonawane K, Suk R, Chiao EY, Chhatwal J, Qiu P, Wilkin T, et al. Oral human papillomavirus infection: differences in prevalence between sexes and concordance with genital human papillomavirus infection, NHANES 2011 to 2014. Ann Intern Med. 2017;167(10):714–24. https://doi.org/10.7326/M17-1363
29. Artemchuk H, Eriksson T, Poljak M, Surcel HM, Dillner J, Lehtinen M, Faust H. Long-term antibody response to human papillomavirus vaccines: up to 12 years of follow-up in the Finnish maternity cohort. J Infect Dis. 2019;219(4):582–9. https://doi.org/10.1093/infdis/jiy545
30. Shimabukuro TT, Su JR, Marquez PL, Mba-Jonas A, Arana JE, Cano MV. Safety of the 9-valent human papillomavirus vaccine. Pediatrics. 2019;144(6):e20191791. https://doi.org/10.1542/peds.2019-1791
31. Ulrikh EA, Urmancheeva AF, Gurkin YuA, Semiglazova DV, Ulrikh DG, Khalimbekova DI, et al. Primary prevention of cervical cancer. Effectiveness, safety, economic feasibility of vaccination. Onkoginekologiya = Oncogynecology. 2018;(4):61–71 (In Russ.)
32. Faust H, Toft L, Sehr P, Müller M, Bonde J, Forslund O, et al. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. Vaccine. 2016;34(13):1559–65. https://doi.org/10.1016/j.vaccine.2016.02.019
33. Stanley M. HPV vaccination in boys and men. Hum Vaccin Immunother. 2014;10(7):2109–11. https://doi.org/10.4161/hv.29137
34. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63(RR-05):1–30.
35. Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer. 2011;105(1):28–37. https://doi.org/10.1038/bjc.2011.185
36. Kreimer AR, Herrero R, Sampson JN, Porras C, Lowy DR, Schiller JT, et al. Evidence for single-dose protection by the bivalent HPV vaccine – Review of the Costa Rica HPV vaccine trial and future research studies. Vaccine. 2018;36(32 Pt A):4774–82. https://doi.org/10.1016/j.vaccine.2017.12.078
37. Safaeian M, Sampson JN, Pan Y, Porras C, Kemp TJ, Herrero R, et al. Durability of protection afforded by fewer doses of the HPV16/18 vaccine: the CVT Trial. J Natl Cancer Inst. 2018;110(2). https://doi.org/10.1093/jnci/djx158
38. Kjaer SK, Nygård M, Dillner J, Brooke Marshall J, Radley D, Li M, et al. A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 nordic countries. Clin Infect Dis. 2018;66(3):339–45. https://doi.org/10.1093/cid/cix797
39. Garland SM, Cheung TH, McNeill S, Petersen LK, Romaguera J, Vazquez-Narvaez J, et al. Safety and immunogenicity of a 9-valent HPV vaccine in females 12–26 years of age who previously received the quadrivalent HPV vaccine. Vaccine. 2015;33(48):6855–64. https://doi.org/10.1016/j.vaccine.2015.08.059
40. Arbyn M, Xu L. Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials. Expert Rev Vaccines. 2018;17(12):1085–91. https://doi.org/10.1080/14760584.2018.1548282
41. Palmer T, Wallace L, Pollock KG, Cuschieri K, Robertson C, Kavanagh K, Cruickshank M. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12–13 in Scotland: retrospective population study. BMJ. 2019;365:l1161. https://doi.org/10.1136/bmj.l1161
42. Drolet M, Bénard É, Pérez N, Brisson M. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497–509. https://doi.org/10.1016/S0140-6736(19)30298-3
43. McClung NM, Gargano JW, Park IU, Whitney E, Abdullah N, Ehlers S, et al. Estimated number of cases of high-grade cervical lesions diagnosed among women – United States, 2008 and 2016. MMWR Morb Mortal Wkly Rep. 2019;68(15):337–43. https://doi.org/10.15585/mmwr.mm6815a1
44. Cleveland AA, Gargano JW, Park IU, Griffin MR, Niccolai LM, Powell M, et al. Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008–2015. Int J Cancer. 2020;146(3):810–8. https://doi.org/10.1002/ijc.32340 45. Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer H, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565–80. https://doi.org/10.1016/S1473-3099(14)71073-4
45. Hall MT, Simms KT, Lew JB, Smith MA, Brotherton JM, Saville M, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2019;4(1):e19–27. https://doi.org/10.1016/S2468-2667(18)30183-X
46. Maybarduk P, Rimmington S. Compulsory Licenses: A tool to improve global access to the HPV vaccine? Am J Law Med. 2009;35(2–3):323–50. https://doi.org/10.1177/009885880903500205
47. Andrus JK, Sherris J, Fitzsimmons JW, Kane MA, Aguado MT. Introduction of human papillomavirus vaccines into developing countries – international strategies for funding and procurement. Vaccine. 2008;26(Suppl 10):K87–K92. https://doi.org/10.1016/j.vaccine.2008.05.003
48. Padmanabhan S, Amin T, Sampat B, Cook-Deegan R, Chandrasekharan S. Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India. Nat Biotechnol. 2010;28:671–8. https://doi.org/10.1038/nbt0710-671
49. Yin F, Wang Y, Chen N, Jiang D, Qiu Y, Wang Y, et al. A novel trivalent HPV 16/18/58 vaccine with anti-HPV 16 and 18 neutralizing antibody responses comparable to those induced by the Gardasil quadrivalent vaccine in rhesus macaque model. Papillomavirus Res. 2017;3:85–90. https://doi.org/10.1016/j.pvr.2017.02.005
50. Schellenbacher C, Roden RBS, Kirnbauer R. Developments in L2-based human papillomavirus (HPV) vaccines. Virus Res. 2017;231:166–175. https://doi.org/10.1016/j.virusres.2016.11.020
51. Schellenbacher C, Huber B, Skoll M, Shafti-Keramat S, Kirnbauer R. Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity. Vaccine. 2019;37(27):3529–34. https://doi.org/10.1016/j.vaccine.2019.05.011
52. Dobson SRM, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309(17):1793–802. https://doi.org/10.1001/jama.2013.1625
53. Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011;7(12):1374–86. https://doi.org/10.4161/hv.7.12.18322
Review
For citations:
Alyautdina O.S., Prilutskaya V.Yu. Ongoing challenges and future directions of human papillomavirus vaccination. Safety and Risk of Pharmacotherapy. 2020;8(3):141-150. (In Russ.) https://doi.org/10.30895/2312-7821-2020-8-3-141-150
Views:
1379
Email this article 